ACTRN12609000109202已完成2 期
ATTAX 3:A randomised phase II study evaluating weekly docetaxel, cisplatin, fluoropyrimidine (wTCF) plus or minus panitumumab in advanced oesophago-gastric cancer to evaluate response.
AGITG -Australasian Gastro-Intestinal Group0 个研究点目标入组 77 人开始时间: 2009年2月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 77
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •a)Age over 18.
- •b)Histological diagnosis of metastatic or locally recurrent oesophago-gastric cancer (squamous cell, adenocarcinoma or undifferentiated carcinoma)
- •c)Any primary oesophago-gastric site (oesophagus, oesophago-gastric junction (OGJ) or stomach)
- •d)Unidimensional measurable disease as assessed by computed tomography (CT) scan (RECIST v1.1 criteria). There must be at least one lesion > or equal to 20mm as measured by conventional computed tomography (CT) scan or > or equal to 10mm as measured by spiral computed tomography (CT) scan. All sites of disease must have been evaluated within 21 days of initiating study treatment and diagnosed by the investigator.
- •e)Prior palliative radiotherapy is allowed provided no concurrent chemotherapy was administered, all radiation toxicities have resolved to grade 1 or less and at least 14 days has elapsed from the last dose of radiotherapy until the start of chemotherapy in ATTAX 3. Furthermore, the site(s) of measurable disease must include at least one that is outside the radiation field unless this site has demonstrated clear progression, prior to randomisation.
- •f)World Health Organisation (WHO) performance status 0, 1 or 2 (Patients who ahave a performance status (PS) 2 should have serum albumin >30 g/L)
- •g)Able to swallow tablets if planned to receive capecitabine
- •h)Adequate bone marrow function with platelets>100x109/L; neutrophils>1.5x109/L and haemoglobin = 9.0g/dL.
- •i)Adequate renal function, with calculated creatinine clearance >50 ml/min based on the Cockcroft-Gault method. Adequate renal function (measured creatinine clearance>50ml/min) assessed by 24 hour urine or glomerular filtration rate (GFR) scan is also acceptable in cases where the Cockcroft-Gault method is considered inaccurate.
- •j)Adequate electrolytes, with serum magnesium level within the normal range and corrected serum calcium within the normal range.
- •k)Adequate hepatic function with serum total bilirubin <1.25 x upper limit of normal range and alanine aminotransferase (ALT)/aspartate aminotransferase (AST) <2.5x upper limit of normal range and alkaline phosphatase <5x upper limit of normal range
- •l)Life expectancy of at least 12 weeks
- •m)Negative pregnancy test and adequate contraceptive precautions if relevant
- •n)Written informed consent for main study AND tissue banking
排除标准
- •a)Medical or psychiatric conditions that compromise the patient’s ability to give informed consent or comply with the study protocol.
- •b)Previous malignant disease other than non-melanotic skin cancer or carcinoma in situ of the uterine cervix or other cancers treated with curative intent > 2 years previously and without evidence of relapse.
- •c)Uncontrolled metastatic disease to the central nervous system. Central Nervous System (CNS) metastases should be treated with surgery and/or radiotherapy and the patient should have stable neurology on a stable dose of steroids for at least 2 weeks.
- •d)Concomitant treatment with brivudine, lamivudine, ribavirin or any other nucleoside analogues.
- •e)Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (e.g. cetuximab) or treatment with small molecule epidermal growth factor receptor (EGFR) inhibitors (e.g. erlotinib).
- •f)Prior chemotherapy agents for metastatic or recurrent disease. Neoadjuvant or adjuvant chemotherapy given alone or with concurrent radiotherapy > 12 months ago for oesophago-gastric cancer is allowed.
- •g)History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline computed tomography (CT) chest scan.
- •h)Known dihydropyrimidine dehydrogenase (DPD) deficiency.
- •i)Pregnancy or breast feeding (All women of childbearing potential must have a negative pregnancy test prior to inclusion into the trial).
- •j)Men or women of childbearing potential (women who are post-menopausal < 52 weeks, not surgically sterilised, or not abstinent) not consenting to use adequate contraception (per institutional standard of care) during the study and after the last investigational product (s) administration (24 weeks for women, 4 weeks for men).
- •k)Clinical evidence of >grade 2 peripheral neuropathy, ie. affecting activities of daily living
- •l)Any uncontrolled concurrent medical condition
- •m)Patients with known malabsorption syndromes (if planning to receive capecitabine).
- •n)Known allergy to the investigational product, to any of its excipients, to monoclonal antibodies, or to any of the components of the chemotherapy regimen
- •o)Any co-morbid disease that would increase risk of toxicity
- •p)Participation in any investigational drug study within the previous 4 weeks
研究者
相似试验
进行中（未招募）
不适用
OGS: A randomized phase II/III study to assess the efficacy of trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous ovarian cancer of peritoneal cancer (GOG-0281)Recurrent low grade serous ovarian or peritoneal cancerMedDRA version: 18.1Level: PTClassification code 10066697Term: Ovarian cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-001627-39-GBHS Greater Glasgow and Clyde250
已完成
2 期
Phase II/III study to investigate the efficacy of 5-aminolaevulinic acid (ALA)-based photodynamic therapy in the treatment of Bowen's disease, actinic keratoses and study the effect of dose fractionation for superficial basal cell carcinomasBowen's diseaseCarcinoma in situ of skinCancerISRCTN93864182Department of Health (UK)
进行中（未招募）
1 期
A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)EUCTR2012-000091-41-GBniversity College London57
招募中
2 期
Dose escalation trial for squamous cell carcinoma of head and neck using FMISO PET CTCTRI/2024/04/065373Varian Medical Systems Inc
已完成
2 期
ATTAXACTRN12606000163505Australasian Gastro-Intestinal Trials Group A(AGITG)100